ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion

Antares Pharma Reports Third Quarter 2021 Financial and Operating Results https://www.globenewswire.com/news-release/2021/11/04/2327256/35385/en/Antares-Pharma-Reports-Third-Quarter-2021-Financial-and-Operating-Results.html Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share

Antares Pharma Enters Into Credit Agreement For Credit Facilities Of Up To $40 Million https://last10k.com/sec-filings/atrs/0001016169-21-000034.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=atrs

Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S. https://finance.yahoo.com/news/antares-pharma-enters-exclusive-license-110000356.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACmcGvCVMgXvJisyH7dENdV43bZ9G9OSnQ1kKolpY7XMcXw_pP1W507Dyb9F7Q1crjWuV7kbV-hAr1VMpRk1YIqYv1GmCx7S1jNC0HOwRHg58A3uV1qMVHt8eWMl_RM62gozApJBgLrzIrSagRGR1HZXr3s1v92xV9vwlDNA9Eo4

Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/09/30/2306251/35385/en/Antares-Pharma-Initiates-Phase-I-Study-For-ATRS-1902-For-Adrenal-Crisis-Rescue.html Pharmacokinetic data results expected in 1Q 2022

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results https://www.globenewswire.com/news-release/2021/08/05/2275394/35385/en/Antares-Pharma-Reports-Second-Quarter-2021-Financial-and-Operating-Results.html Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share ...

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/07/22/2267319/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-IND-Application-for-ATRS-1902-for-Adrenal-Crisis-Rescue.html

Bin hier auch mal drin.

Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction https://finance.yahoo.com/news/antares-pharma-announces-partner-idorsia-123000136.html

Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/06/22/2251054/35385/en/Antares-Pharma-Announces-Submission-of-IND-Application-for-ATRS-1902-for-Adrenal-Crisis-Rescue.html

https://clinicaltrials.gov/ct2/show/NCT04879589 Phase 1 Study of ATRS-2002 in Healthy Male Adults

Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results https://www.globenewswire.com/news-release/2021/03/02/2185091/0/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-and-Operating-Results.html Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million, including a Net Tax Benefit of $46.3 million ...

Watchliste aufgenommen

👀

Bin heute eingestiegen, scheint aber ruhig zu sein hier!

Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million https://www.globenewswire.com/news-release/2021/01/11/2156237/0/en/Antares-Pharma-Announces-Full-Year-2021-Revenue-Guidance-of-175-200-Million.html Company updates full-year 2020 revenue guidance to $145-150 million

Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results https://www.globenewswire.com/news-release/2020/11/05/2120889/0/en/Antares-Pharma-Reports-Strong-Third-Quarter-2020-Financial-and-Operating-Results.html Third Quarter 2020 Revenue Increases 17% Year-Over-Year to $40.0 Million Third Quarter 2020 Net Income of $5.0 Million, or EPS of $0.03 ...